UK markets closed

Orion Oyj (ORINY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
20.000.00 (0.00%)
At close: 11:03AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.00
Open20.00
BidN/A x N/A
AskN/A x N/A
Day's range20.00 - 20.00
52-week range18.20 - 22.40
Volume58
Avg. volume1
Market cap6.591B
Beta (5Y monthly)0.50
PE ratio (TTM)27.40
EPS (TTM)0.73
Earnings dateN/A
Forward dividend & yield0.83 (4.14%)
Ex-dividend date24 Mar 2022
1y target estN/A
  • Globe Newswire

    U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

    ORION CORPORATION PRESS RELEASE 8 August 2022 at 9:30 EEST U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC).Approval under the FDA’s Real-Time Oncology Review (RTOR) pilot prog

  • Globe Newswire

    Orion Corporation: Managers’ transactions – Virve Laitinen

    ORION CORPORATION MANAGERS’ TRANSACTIONS 5 August 2022 at 11.15 EEST Orion Corporation: Managers’ transactions – Virve Laitinen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Virve

  • Globe Newswire

    Orion Group Half-Year Financial Report 1–6/2022

    ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2022 15 JULY 2022 at 12:00 EEST Orion Group Half-Year Financial Report 1–6/2022 This is a summary or Orion’s Half-Year Financial Report 1–6/2022. The complete report is attached to this stock exchange release and is available at https://www.orion.fi/en/Orion-group/investors/financial-reviews-and-presentations/ Net sales totalled EUR 554 million (EUR 524 million in 2021). Operating profit was EUR 153 (146) million.Profit before taxes was EUR 155 (1